European, Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Onasemnogene-abeparvovec (Primary)
- Indications Spinal muscular atrophy
- Focus Registrational; Therapeutic Use
- Acronyms STR1VE EU; STRIVE-EU
- Sponsors AveXis
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2018 Status changed from not yet recruiting to recruiting.
- 25 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.